# EDGAR Filing Document

**Accession Number:** 0000918697
**File Stem:** 0000950157-25-000967
**Filing Date:** 2025-11
**Character Count:** 28486
**Document Hash:** 09bee4482c2bf9e99ab4255f3ab0cff9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950157-25-000967.hdr.sgml**: 20251124

**ACCESSION NUMBER**: 0000950157-25-000967

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20251124

**DATE AS OF CHANGE**: 20251124

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SELECT MEDICAL HOLDINGS CORP
- **CENTRAL INDEX KEY:** 0001320414
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOSPITALS [8060]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-85191
- **FILM NUMBER:** 251513786

**BUSINESS ADDRESS:**
- **STREET 1:** C/O SELECT MEDICAL CORP
- **STREET 2:** 4714 GETTYSBURG RD
- **CITY:** MECHANICSBURG
- **STATE:** PA
- **ZIP:** 17055
- **BUSINESS PHONE:** 717-972-1100

**MAIL ADDRESS:**
- **STREET 1:** C/O SELECT MEDICAL CORP
- **STREET 2:** 4714 GETTYSBURG RD
- **CITY:** MECHANICSBURG
- **STATE:** PA
- **ZIP:** 17055
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORTENZIO ROBERT A
- **CENTRAL INDEX KEY:** 0000918697
- **STANDARD INDUSTRIAL CLASSIFICATION:** UNKNOWN SIC - 0000 [0000]

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** PA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 4718 OLD GETTYSBURG RD
- **STREET 2:** POST OFFICE BOX 2034
- **CITY:** MECHANICSBURG
- **STATE:** PA
- **ZIP:** 30309

## Exhibit 99.1

**Exhibit 99.1**<br>

#### Joint Filing Statement

We, the undersigned, hereby express our agreement that the attached Schedule 13D is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13D as to any of the undersigned upon such person giving written notice thereof to each of the other persons signatory hereto, at the principal office thereof.

Date: November 24, 2025

---

| | |
|:---|:---|
| By: | /s/ Robert A. Ortenzio  |
| Name: | Robert A. Ortenzio |

---

---

| | |
|:---|:---|
| By: | /s/ Martin F. Jackson |
| Name: | Martin F. Jackson |

---

---

| | |
|:---|:---|
| **The Estate of Rocco A. Ortenzio** | **The Estate of Rocco A. Ortenzio** |
| By: | /s/ Robert A. Ortenzio |
| Name: | Robert A. Ortenzio |
| Title: | Authorized Signatory |

---

## Exhibit 99.2

**Exhibit 99.2**<br>

November 24, 2025

Board of Directors

Select Medical Holdings Corporation

4714 Gettysburg Road

Mechanicsburg, Pennsylvania 17055

Re: Non-Binding Offer to Acquire Select Medical Holdings Corporation ("SEM" or the "Company")

Dear Members of the Board:

I am pleased to submit this non-binding indication of interest (the "Proposal") to acquire all the Company's outstanding shares of common stock (the "Potential Transaction") at an all-cash purchase price of $16.00 to $16.20 per share (the "Offer Price"). The Offer Price represents a premium of 21.0% to 22.5% to the Company's 90-day volume-weighted average daily trading price of $13.22 per share as of November 21, 2025. As such, this Proposal would provide the Company's stockholders with an opportunity to realize immediate liquidity at a significant premium.

As the Executive Chairman and a Co-Founder of SEM, I believe that I am uniquely positioned to timely execute an acquisition of the Company on attractive terms for the Company's shareholders. First, I have deep familiarity with SEM's business and am prepared to move forward with an expedited due diligence process and to negotiate and execute definitive transaction documentation within eight weeks of submitting this Proposal. Second, my equity partners and I have intimate knowledge and operating experience in each of the Company's segments—Critical Illness Recovery Hospitals, Rehabilitation Hospitals, Outpatient Rehabilitation and other businesses—including longstanding relationships with the Company's joint venture partners and other healthcare providers. Finally, my equity partners' and my status as "Permitted Holders" under certain of the Company's existing indebtedness would permit such indebtedness to remain outstanding following completion of the transaction, facilitating our ability to finance the Proposal on attractive terms.

This Proposal is not subject to any financing conditions and would be fully financed by committed equity financing from funds affiliated with Welsh, Carson, Anderson & Stowe ("WCAS") and committed debt financing from J.P. Morgan and Wells Fargo. Based on publicly available information, J.P. Morgan and Wells Fargo have provided me with a commitment letter for the debt portion of the financing, and WCAS has indicated to me high confidence in its ability to provide committed equity financing to support this Proposal, subject to completion of diligence. Additionally, Martin Jackson, SEM's Senior Executive Vice President of Strategic Finance & Operations, would be part of the equity consortium supporting this Proposal (the "Consortium"). Currently, members of the Consortium and its affiliates hold, collectively, approximately 12.4% of the outstanding shares of the Company, and will agree to roll over such shares into equity of the surviving company. I may, at the appropriate time and in consultation with the board of directors of SEM, invite other members of management or the board of directors of the Company to roll over their outstanding equity of the Company as well.

While any Potential Transaction will be subject to satisfactory diligence and customary approvals and closing conditions, I do not anticipate substantial regulatory or other hurdles or delays to consummating a Potential Transaction. I expect the Company's board of directors will appoint a Special Committee comprised entirely of disinterested directors to evaluate this Proposal. I will not pursue this Proposal without approval of the Special Committee, advised by independent legal and financial advisors, and further expect that the definitive merger agreement will include a non-waivable condition requiring the approval of a majority of the votes cast by the shares of SEM stock that are not held by members of the Consortium and its affiliates.

------

As required by applicable law, I intend to promptly file a Schedule 13D, including a copy of this letter, with the Securities and Exchange Commission.

This letter and the Proposal constitute a non-binding indication of my interest in a transaction with the Company and are not intended to create a legally binding obligation or agreement of the Consortium, the Company or of their respective shareholders, representatives or affiliates concerning the Potential Transaction, which is expressly subject to the negotiation and execution of appropriate and acceptable definitive agreements. I reserve the right to withdraw or modify this Proposal at any time.

I look forward to the opportunity to work with the Special Committee to move quickly towards a successful transaction.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| By: | /s/ Robert Ortenzio |
| Name: | Robert Ortenzio |
| Title: | Executive Chairman and Co-Founder, Select Medical Corporation |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**SELECT MEDICAL HOLDINGS CORP**

*(Name of Issuer)*

**Common Stock, par value $0.001**

*(Title of Class of Securities)*

**81619Q105**

*(CUSIP Number)*

**Robert A. Ortenzio**<br>4714 Gettysburg Road<br>P.O. Box 2034<br>Mechanicsburg PA 17055<br>717 972-1100

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/24/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **81619Q105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ORTENZIO ROBERT A** | Name of reporting person<br>**ORTENZIO ROBERT A** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**7081788.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6937947.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**7081788.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6937947.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**14019735.00** | Aggregate amount beneficially owned by each reporting person<br>**14019735.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.3%** | Percent of class represented by amount in Row (11)<br>**11.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1.  Items 8, 10, 11 and 13 include 7,081,788 shares over which the Reporting Person has the sole power to vote and dispose of as well as the following shares that the Reporting Person may be deemed to beneficially own, as the Reporting Person may be deemed to have current shared power to vote or direct the vote of and to dispose of or direct the disposition therefor:  (a) 200,000 shares held by the Robert and Angela Ortenzio Family Foundation, of which the Reporting Person is a co-trustee, (b) 532,152 shares held by the Rocco and Nancy Ortenzio Family Foundation, of which the Reporting Person is a co-trustee, (c) 1,279,000 shares owned by the Robert A. Ortenzio Descendants Trust, for which the Reporting Person serves as a member of the board of directors of Select Asset Management & Trust LLC (the "Select Trustee"), a co-trustee, (d) 280,415 shares held by the Robert A. Ortenzio April 2014 Trust for Kevin M. Ortenzio, for which the Reporting Person serves as a member of the board of directors of the Select Trustee, a co-trustee, (e) 280,415 shares held by the Robert A. Ortenzio April 2014 Trust for Bryan A. Ortenzio for which Mr. Robert A. Ortenzio, for which the Reporting Person serves as a member of the board of directors of the Select Trustee, a co-trustee, (f) 280,415 shares held by the Robert A. Ortenzio April 2014 Trust for Madeline G. Ortenzio, for which the Reporting Person serves as a member of the board of directors of the Select Trustee, a co-trustee, (g) 4,028,767 shares held by the Rocco A. Ortenzio Revocable Trust, of which the Reporting Person is a co-trustee, (h) 16,182 shares beneficially owned by the Estate of Rocco A. Ortenzio through Select AP Investors, L.P., for which the Reporting Person may be deemed to exercise control in his capacity as a trustee of such Estate, (i) 30,601 shares beneficially owned by the Estate of Rocco A. Ortenzio through Select Investments III, L.P., for which the Reporting Person may be deemed to exercise control in his capacity as a trustee of such Estate, and (j) 10,000 shares held by the spouse of the deceased Rocco A. Ortenzio, over which the Reporting Person shares a power of attorney.

2. The percentage in Item 13 is based on 123,817,591 Common Stock shares outstanding of Select Medical Holdings Corporation as of September 30, 2025.

| **CUSIP No.** | **81619Q105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**JACKSON MARTIN F** | Name of reporting person<br>**JACKSON MARTIN F** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1383421.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2634.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1383421.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2634.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1383421.00** | Aggregate amount beneficially owned by each reporting person<br>**1383421.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.1%** | Percent of class represented by amount in Row (11)<br>**1.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1. Items 8 and 10 contain 2,634 shares beneficially owned by the Reporting Person's child over whom the Reporting Person is a court-appointed guardian. The Reporting Person disclaims beneficial ownership in all such shares.

2. The percentage in Item 13 is based on 123,817,591 Common Stock shares outstanding of Select Medical Holdings Corporation as of September 30, 2025.

| **CUSIP No.** | **81619Q105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ESTATE OF ROCCO A. ORTENZIO** | Name of reporting person<br>**ESTATE OF ROCCO A. ORTENZIO** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4085550.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4085550.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4085550.00** | Aggregate amount beneficially owned by each reporting person<br>**4085550.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.3%** | Percent of class represented by amount in Row (11)<br>**3.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** 1. Items 8, 10, 11 and 13 include the following shares that the Reporting Person may be deemed to beneficially own, as the Reporting Person may be deemed to have current shared power to vote or direct the vote of and to dispose of or direct the disposition therefor:  (a) 4,028,767 shares held by the Rocco A. Ortenzio Revocable Trust, (b) 16,182 shares held by Select AP Investors, L.P., (c) 30,601 shares held through Select Investments III, L.P., and (d) 10,000 shares held by the spouse of the deceased Rocco A. Ortenzio.

2. The percentage in Item 13 is based on 123,817,591 Common Stock shares outstanding of Select Medical Holdings Corporation as of September 30, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001

**(b) Name of Issuer:**
SELECT MEDICAL HOLDINGS CORP

**(c) Address of Issuer's Principal Executive Offices:**
4714 Gettysburg Road, P.O. Box 2034, Mechanicsburg, PA, 17055

This Schedule 13D relates to the Common Stock shares, par value $0.001 (the "Shares"), issued by Select Medical Holdings Corp (the "Issuer"). The Issuer's principal executive office is located at 4714 Gettysburg Road, Mechanicsburg, Pennsylvania 17055.

**Item 4. Purpose of Transaction**

Mr. Ortenzio has filed a Statement of Beneficial Ownership on Schedule 13G and amendments thereto with respect to his beneficial ownership of his Shares, a portion of which were acquired prior to the initial public offering of the shares of the Issuer and the remainder of which have been acquired by Mr. Ortenzio as compensation for his roles as an officer and director with the Issuer or otherwise purchased for investment purposes. As a result of the actions described below, Mr. Ortenzio is now converting his beneficial ownership filing on Schedule 13G to a filing on this Schedule 13D.

Mr. Jackson acquired beneficial ownership of his shares of the Issuer as compensation for his role as an employee and officer of the Issuer.

The Estate of Rocco Ortenzio has filed a Statement of Beneficial Ownership on Schedule 13G and amendments thereto with respect to its beneficial ownership of its Shares, a portion of which were acquired prior to the initial public offering of the shares of the Issuer and the remainder of which were acquired by Rocco A. Ortenzio as compensation for his roles as an officer and director with the Issuer or otherwise purchased for investment purposes. As a result of the actions described below, the Estate of Rocco A. Ortenzio is now converting its beneficial ownership filing on Schedule 13G to a filing on this Schedule 13D.

Mr. Ortenzio serves as the executive chairman of the Board. Mr. Jackson is the Senior Executive Vice President of Strategic Finance and Operations at the Issuer. Therefore, such Reporting Persons regularly engage in discussions with management of the Issuer, the Board, other shareholders of the Issuer and other relevant parties, which discussions may include matters ranging from the operations and conduct of the Issuer's business to considering or exploring extraordinary corporate transactions, including the events listed in clauses (a) through (j) of Item 4 of Schedule 13D. 

On November 24, 2025, the Reporting Persons, including Mr. Ortenzio acting on behalf of the Estate of Rocco A. Ortenzio, agreed to submit a proposal to the Issuer related to a potential transaction whereby the Reporting Persons and certain other financing sources would acquire all of the issued and outstanding Shares not already owned by the Reporting Persons. On November 24, 2025, Mr. Ortenzio delivered a non-binding proposal (the "Proposal Letter") to the Board to offer to acquire all such Shares at a price of $16.00 to $16.20 per share, payable in cash (the "Proposal"). The Proposal is subject to completion by the Reporting Persons of customary due diligence.

The foregoing description of the Proposal Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Proposal Letter, which is filed as Exhibit 99.2 hereto and is incorporated by reference into this Item 4.

There can be no assurance that any discussions that may occur between the Reporting Persons and the Issuer with respect to the Proposal will result in the entry into a definitive agreement concerning a transaction or, if such a definitive agreement is reached, will result in the consummation of a transaction provided for in such definitive agreement. Discussions concerning a transaction may be terminated at any time and without prior notice. Entry into a definitive agreement concerning a transaction and the consummation of any such transaction will be subject to a number of contingencies that are beyond the control of the Reporting Persons, including the approval of the Board, and the satisfaction of any conditions to the consummation of a transaction set forth in any such definitive agreement, including receipt of all necessary regulatory approvals.

Except as may be required by law, the Reporting Persons do not intend to disclose developments with respect to the foregoing unless and until the Board and the Reporting Persons have approved a specific transaction, if any, and the Reporting Persons and the Board have then entered into a definitive agreement to effect such transaction or discussions concerning such transaction have been terminated.

If the transaction described in the Proposal Letter is not consummated, the Reporting Persons and their affiliates will continue to regularly review and assess their investment in the Issuer and depending on market conditions and other factors may determine, from time to time, to engage in any of the events set forth in clauses (a) through (j) of Item 4 of Schedule 13D. Any Reporting Person may from time to time acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market, block trades or privately negotiated transactions. Any actions any Reporting Person might undertake with respect to its investment in the Issuer may be made at any time and from time to time and will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: ongoing evaluation of the Issuer's business, financial condition, operations, prospects and strategic alternatives; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; tax considerations; liquidity of the Issuer's securities; and other factors and future developments.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate number and percentage of Shares beneficially owned by each Reporting Person (on the basis of a total of 123,817,591 Shares outstanding of the Issuer as of September 30, 2025) is as follows:

**(b)**
Robert A. Ortenzio

(a) The following amount of shares may be deemed beneficially owned by Mr. Ortenzio: 14,019,735;  Percentage: 11.3%.

(b) Mr. Ortenzio may be deemed to have (i) the sole power to vote or direct the vote of and to dispose of or to direct the disposition of 7,081,788 Shares and (ii) the current shared power to vote or direct the vote of and to dispose of or direct the disposition of 6,937,947 Shares (including (a) 200,000 Shares held by the Robert and Angela Ortenzio Family Foundation, of which the Mr. Ortenzio is a co-trustee, (b) 532,152 Shares held by the Rocco and Nancy Ortenzio Family Foundation, of which the Mr. Ortenzio is a co-trustee, (c) 1,279,000 Shares owned by the Robert A. Ortenzio Descendants Trust, for which the Mr. Ortenzio serves as a member of the board of directors of Select Asset Management & Trust LLC (the "Select Trustee"), a co-trustee, (d) 280,415 Shares held by the Robert A. Ortenzio April 2014 Trust for Kevin M. Ortenzio, for which the Mr. Ortenzio serves as a member of the board of directors of the Select Trustee, a co-trustee, (e) 280,415 Shares held by the Robert A. Ortenzio April 2014 Trust for Bryan A. Ortenzio for which Mr. Robert A. Ortenzio, for which the Mr. Ortenzio serves as a member of the board of directors of the Select Trustee, a co-trustee, (f) 280,415 Shares held by the Robert A. Ortenzio April 2014 Trust for Madeline G. Ortenzio, for which the Mr. Ortenzio serves as a member of the board of directors of the Select Trustee, a co-trustee, (g) 4,028,767 Shares held by the Rocco A. Ortenzio Revocable Trust, of which the Mr. Ortenzio is a co-trustee, (h) 16,182 Shares beneficially owned by the Estate of Rocco A. Ortenzio through Select AP Investors, L.P., for which the Reporting Person may be deemed to exercise control in his capacity as a trustee of such Estate, (i) 30,601 Shares beneficially owned by the Estate of Rocco A. Ortenzio through Select Investments III, L.P., for which the Reporting Person may be deemed to exercise control in his capacity as a trustee of such Estate, and (j) 10,000 Shares held by the spouse of the deceased Rocco A. Ortenzio, over which the Mr. Ortenzio Shares a power of attorney).

Martin F. Jackson:

(a) Amount of shares beneficially owned: 1,383,421;  Percentage: 1.1%.

(b) Mr. Jackson may be deemed to have (i) the sole power to vote or to direct the vote of and to dispose or direct the disposition of 1,383,421 Shares and (ii) the shared power to vote or to direct the vote of and to dispose or direct the disposition of 2,634 Shares held by Mr. Jackson's child, over whom he is a court-appointed guardian. Mr. Jackson disclaims the beneficial ownership of all Shares not directly owned by him. 

The Estate of Rocco A. Ortenzio:

(a) Amount of shares beneficially owned: 4,085,550;  Percentage: 3.3%.

(b) The Estate of Rocco A. Ortenzio may be deemed to have the current shared power to vote or direct the vote of and to dispose of or direct the disposition of 6,937,947 Shares (including (a) 4,028,767 Shares held by the Rocco A. Ortenzio Revocable Trust, (b) 16,182 shares held by Select AP Investors, L.P., (c) 30,601 Shares held through Select Investments III, L.P., and (d) 10,000 Shares held by the spouse of the deceased Rocco A. Ortenzio).

**(c)**
No transactions in Issuer Stock were affected by, or with respect to, the Reporting Persons listed in Item 2 within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Items 3, 4, and 5 (a)-(b) is hereby incorporated by reference in this Item 6. The descriptions of the any contracts, arrangements, understandings, or relationships in Items 3, 4, and 5(a)-(b) in this Item 6 are not intended to be complete and are qualified in their entirety by reference to such documents and descriptions and are hereby incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ORTENZIO ROBERT A

**Signature:** /s/ Robert A. Ortenzio

**Name/Title:** Robert A. Ortenzio

**Date:** 11/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** JACKSON MARTIN F

**Signature:** /s/ Martin F. Jackson

**Name/Title:** Martin F. Jackson

**Date:** 11/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ESTATE OF ROCCO A. ORTENZIO

**Signature:** /s/ Robert A. Ortenzio

**Name/Title:** Robert A. Ortenzio, Authorized Signatory

**Date:** 11/24/2025